文献速递慢性肾脏病

血浆生物标志物可改善1型糖尿病成人糖尿病肾病的12年预测:CACTI研究

Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

CACTI研究纳入527例1型糖尿病成人,随访12.1年,评估基线血浆肾损伤生物标志物对糖尿病肾病(DKD)的预测价值。主成分分析提取两个成分,仅成分2(β2微球蛋白、胱抑素C、NGAL、骨桥蛋白)与ACR升高、eGFR下降及新发肾功能受损独立相关,且加入传统风险因素后显著改善对新发肾功能受损的预测。

要点

  • 成分2生物标志物组合与12年ACR升高和eGFR下降独立相关。
  • 成分2与新发肾功能受损相关,OR 2.08(95%CI 1.18-3.67)。
  • 成分2加入传统风险因素可改善对新发肾功能受损的预测。

核心结论

  • 血浆肾损伤生物标志物有助于预测1型糖尿病成人糖尿病肾病的发生发展。

研究设计与样本

  • CACTI研究纳入527例1型糖尿病成人(女性53%),基线2002-04年,平均年龄39.6±9.0岁,糖尿病中位病程24.8年,随访12.1±1.5年。

主要发现

  • 主成分分析成分2(β2微球蛋白、胱抑素C、NGAL、骨桥蛋白)与log modulus ACR升高相关(β±SE:0.16±0.07,P=0.02)。
  • 成分2与eGFR下降相关(β±SE:-2.56±0.97,P=0.009),校正传统风险因素后仍显著。
  • 成分2与新发肾功能受损相关(OR 2.08,95%CI 1.18-3.67,P=0.01),校正传统风险因素后仍显著。
  • 成分2加入传统风险因素后,对新发肾功能受损的C统计量改善(ΔAUC:0.02±0.01,P=0.049),29%非事件被正确重分类(P<0.0001)。

关键数值与推荐

  • 白蛋白尿定义为ACR≥30 mg/g。
  • 肾功能受损定义为eGFR<60 mL/min/1.73 m2。
  • eGFR采用CKD-EPI肌酐公式估算。

临床怎么用

  • 在1型糖尿病成人中,可考虑检测血浆肾损伤生物标志物组合(成分2)以辅助预测糖尿病肾病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of the study was to determine whether plasma biomarkers of kidney injury improve the prediction of diabetic kidney disease (DKD) in adults with type 1 diabetes (T1D) over a period of 12 years. METHODS: Participants (n = 527, 53% females) in the Coronary Artery Calcification in T1D (CACTI) Study were examined during 2002-04, at a mean (± standard deviation) age of 39.6 ± 9.0 years with 24.8 years as the median duration of diabetes. Urine albumin-to-creatinine (ACR) and estimated glomerular filtration rate (eGFR) by CKD-EPI (chronic kidney disease epidemiology collaboration) creatinine were measured at the baseline and after mean follow-up of 12.1 ± 1.5 years. Albuminuria was defined as ACR ≥30 mg/g and impaired GFR as eGFR <60 mL/min/1.73 m2. Kidney injury biomarkers (Meso Scale Diagnostics) were measured on stored baseline plasma samples. A principal component analysis (PCA) identified two components: (i) kidney injury molecule-1, calbindin, osteoactivin, trefoil factor 3 and vascular endothelial growth factor; and (ii) β-2 microglobulin, cystatin C, neutrophil gelatinase-associated lipocalin and osteopontin that were used in the multivariable regression analyses. RESULTS: Component 2 of the PCA was associated with increase in log modulus ACR [β ± standard error (SE): 0.16 ± 0.07, P = 0.02] and eGFR (β ± SE: -2.56 ± 0.97, P = 0.009) over a period of 12 years after adjusting for traditional risk factors (age, sex, HbA1c, low-density lipoprotein cholesterol and systolic blood pressure and baseline eGFR/baseline ACR). Only Component 2 of the PCA was associated with incident-impaired GFR (odds ratio 2.08, 95% confidence interval 1.18-3.67, P = 0.01), adjusting for traditional risk factors. The addition of Component 2 to traditional risk factors significantly improved C-statistics and net-reclassification improvement for incident-impaired GFR (ΔAUC: 0.02 ± 0.01, P = 0.049, and 29% non-events correctly reclassified, P < 0.0001). CONCLUSIONS: Plasma kidney injury biomarkers can help predict development of DKD in T1D.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Bjornstad P, Pyle L, Cherney DZI, et al. Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study. Nephrol Dial Transplant. 2018. PMID: 28992280. doi:10.1093/ndt/gfx255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。